WuXi Biologics has launched the E coli expression system, EffiX, designed to enhance the production of recombinant proteins and plasmid DNA (pDNA). The worldwide market for microbial-derived products ...

and Controls (CMC) strategy. Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are excited to upgrade our microbial solutions with the innovative EffiX™ platform, which offers our clients ...

A year after the Biosecure Act was introduced, WuXi AppTec’s US revenue growth continued to drop significantly, and the ...

With the fate of the BIOSECURE Act currently in limbo, WuXi AppTec is looking on the brighter side for 2025. | With the fate of the BIOSECURE Act currently in limbo, WuXi AppTec is looking on the ...

The company was ranked top in its industry and received a Top 1% S&P Global Corporate Sustainability Assessment (CSA) Score, marking the third year WuXi Biologics has received this highest level ...

WuXi Biologics differentiates itself from other well-established global contract development and manufacturing organizations, with its "follow-and-win the molecule" and "global dual-sourcing ...

and Controls (CMC) strategy. Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are excited to upgrade our microbial solutions with the innovative EffiX™ platform, which offers our clients ...

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been included in the S&P Global Sustainability ...